Harsimran Sachdeva Singh, MD, MSc
Director, Cornell Center for Adult Congenital Heart Disease, New York Presbyterian Hospital
Interventional Cardiology-Congenital and Structural Heart Interventions, Weill Cornell Medical College-New York Presbyterian Hospital
Assistant Professor of Medicine & Pediatrics
Weill Cornell Medical College
Adjunct Assistant Professor of Medicine
Columbia University College of Physicians & Surgeons, New York, USA
Dr. Singh is an Adult Congenital Heart Disease Specialist and Interventional Cardiologist at Weill Cornell Medical College, New York Presbyterian Hospital in New York City, USA. Dr. Singh grew up in Lancaster, Pennsylvania, earning his undergraduate education in Molecular Biology from Princeton University and his Medical Degree from Yale University School of Medicine. He completed his post-graduate training in Medicine and Cardiology at University of California, San Francisco and Columbia University – New York Presbyterian Hospital. He trained in Adult Congenital Heart Disease and Structural Interventional Cardiology in Canada at Toronto Congenital Cardiac Centre for Adults at Toronto General Hospital. He now heads the Adult Congenital Heart Disease program at Weill Cornell Medical College -New York Presbyterian Hospital as a Clinical and Interventional Specialist.
His research interests include: Structural interventions and congenital heart disease in the pediatric-to-adult population.
HONORS AND AWARDS
• (January 2015-Present) David S. Blumenthal Assistant Professor of Medicine-David S. Blumenthal Professorship is awarded to an assistant professor who has demonstrated remarkable potential and commitment in the field of cardiology
• (2010) House staff Teaching Award by the Department of Internal Medicine-Selected as the Fellow of the Year for teaching & clinical service to the department – Columbia-NY Presbyterian Hospital
• (2009) Coronary Interventions Fellowship Award-Travel grant awarded by SCRIPS to attend the 20th Annual SCRIPS conference on Coronary Interventions moderated by Dr. Paul Teirstein
• (2006-2007) Alpha Omega Alpha-Elected into medical honor society during residency at UCSF-selected by the graduating medical school class for excellence in teaching and scholarship (2007)
• Resident Teaching Fellowship-Invitational fellowship to optimize house-staff teaching through optimizing curriculum and teaching methodology
• (2004) MD Cum Laude-Graduated MD cum laude signifying placement in top 10% of the medical school graduating class
• (2004) John P. Peters Prize-Awarded to the outstanding medical student thesis completed in the field of internal medicine or endocrinology
• (2004) Medical School Marshal-Selected to perform the duties of Class Marshall representing the graduates during commencement exercises
• (2004) Departmental Honors-Awarded for medical school thesis in partial fulfilment of doctorate of medicine requirements
• (2002-2003) Doris Duke Clinical Research Fellowship-A one-year scholarship that provides combined didactic and mentored clinical research training. Completed at Yale School of Medicine in the Department of Internal Medicine
• (Summer of 2000) Yale University School of Medicine Student Research Grant-Summer grant to undergo Nephrology & Cardiothoracic surgery research
• (1998) Rotary Ambassadorial Scholarship-Winner of the Rotary Ambassadorial Scholarship for one-year study abroad in public health
• (1997)Princeton University Molecular Research Fellowship for research in the Department of Molecular Biology
• (1996) Merck/Project-55 Scholar-Winner of scholarship for internship in public health-joint fellowship between Montgomery County Health Department, the American Academy of Pediatrics, & Merck Vaccine Division
PROFESSIONAL MEMBERSHIPS (MEDICAL AND SCIENTIFIC SOCIETIES)
Adult Congenital Heart Disease
• Member Congenital Heart Information Network Since 2012
• Member International Society of Adult Congenital Heart Disease Since 2011
• Member Adult Congenital Heart Association Since 2009
Cardiology and Interventional Cardiology
• Fellow American College of Cardiology Since 2013
• Fellow Society for Cardiovascular Angiography & Interventions Since 2013
• Member American Heart Association Since 2007
• Member Alpha Omega Alpha Since 2006
• Member American College of Physicians Since 2000
• Member American Medical Association Since 1999
RESEARCH ARTICLES IN PEER-REVIEWED JOURNALS
1. Swaminathan RV, Rao SV, McCoy LA, et al. Hospital length of stay and clinical outcomes in older STEMI patents after primary PCI. A report from the National Cardiovascular Data Registry. Journal of American College of Cardiology. 2015; 65(12): 1161-1171. doi: 10.1016/j.jacc.2015.01.028
2. Deaño RC, Shah AM, Khan Z, et al. Giant coronary aneurysm diagnosed as an incidental mediastinal mass. JACC: Cardiovascular Interventions. 2015; 8(1): 114-115. doi: 10.1016/j.jcin.2014.07.021.
3. Kim LK, Yang DC, Swaminathan RV, et al. Comparison of trends and outcomes of carotid artery stenting and endarterectomy in the United States, 2001 to 2010. Circ Cardiovasc Interv. 2014; (7)5: 692-700. doi: 10.1161/CIRCINTERVENTIONS.113.001338
4. Kim LK, Feldman DN, Swaminathan RV, et al. Rate of percutaneous coronary intervention for the management of acute coronary syndromes and stable coronary artery disease in the United States (2007 to 2011). Am J Cardiol. 2014; 114(7): 1003-1010. doi: 10.1016/j.amjcard.2014.07.013
5. Singh HS, Dangas G, Guagliumi G, et al. Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in st-segment elevation myocardial infarction from the HORIZONS-AMI Trial. American Journal of Cardiology. 2012; 110(7): 940-947. doi: 10.1016/j.amjcard.2012.05.026
6. Singh HS, Bibbins-Domingo K, Ali S, Wu A, Schiller NB, Whooley MA. N-Terminal Pro-B-type natriuretic peptide and inducible ischemia in patients with coronary heart disease from the heart and soul study. Clinical Cardiology. 2009; 32(8): 447-453. doi: 10.1002/clc.20569
7. Gross CP, Filardo G, Singh HS, Freedman AN, Farrell MH. The relation between projected breast cancer risk, perceived cancer risk and mammography use: results from the national health interview survey. Journal of General Internal Medicine. 2006; 21(2): 158-164. doi: 10.1111/j.1525-1497.2005.00312.x
8. Singh HS, Yue N, Azimi N, Nath R, Roberts KB, Pfau S. Relation of clinical success in coronary brachytherapy to dose. American Journal of Cardiology. 2004; 94(7): 847-852. doi: 10.1016/j.amjcard.2004.06.016
9. Lovoulos C, Tittle S, Goldstein L, et al. Right ventricle-sparing heart transplantation effective against iatrogenic pulmonary hypertension. Journal of Heart & Lung Transplantation. 2004; 23(2): 236-241. doi: 10.1016/S1053-2498(03)00110-4
10. Singh HS, Roberts KB, Yue N, et al. Brachytherapy for in-stent restenosis in general interventional practice: a single institutions experience using four radiation devices. Cardiovascular Radiation Medicine. 2003; 4(3): 126-132. doi: 10.1016/S1522-1865(03)00183-5
11. Tittle SL, Lynch RJ, Cole PE, et al. Midterm follow-up of penetrating ulcer and intramural hematoma of the aorta. Journal of Thoracic & Cardiovascular Surgery. 2002; 123(6): 1051-1059. doi: 10.1067/mtc.2002.121681
12. Shim SS, Grant ER, Singh HS, Gallagher MJ, Lynch DR. Actions of butyrophenones and other antipsychotic agents at nmda receptors: relationship with clinical effects and structural considerations. Neurochemistry International. 1999; 34: 167-175. doi: 10.1016/S0197-0186(98)00085-0
BOOK CHAPTERS, REVIEWS, AND EDITORIALS
1. Singh HS, Benson L, Osten M, Horlick E. Percutaneous pulmonary valve implantation. Interventional procedures for structural heart disease. In: Lasala JM, Rogers JH, eds. Philadelphia, Elseiver; 2014: 107-122.
2. Singh HS, Horlick E, Osten M, Benson L. Interventional cardiology in adults with congenital heart disease. Nature Reviews-Cardiology. 2013; 10(11): 662-678. doi: 10.1038/nrcardio.2013.127
3. Singh HS, Nagy C, Wan A, Osten M, Benson L, Horlick E. Complex interventions in the adult with congenital heart disease: percutaneous solutions for venous baffles, coronary artery fistulas, and ruptured sinus of valsalva aneurysms. Interventional Cardiology Clinics. 2013; 2(1): 153-172. doi: 10.1016/j.iccl.2012.09.010
4. Iyer V, Singh HS, Reiffel JA. Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use. Journal of Clinical Pharmacy and Therapeutics. 2012; 17(3): 237-247.
5. Singh HS. Commentary on Sandoval et al paper does anticoagulation in eisenmenger syndrome impact long-term survival? Journal Watch-International Society of Adult Congenital Heart Disease. 2012.
6. Singh HS, Osten M, Horlick E. Future horizons for catheter based interventions in adult congenital and structural heart disease. Future Cardiology. 2012; 8(2): 203-213.
7. Singh HS, Osten M, Horlick E. Percutaneous coronary interventions. In: Korenstein D, Lynn R, eds. Physicians information and education resource (PIER) Philadelphia: American College of Physicians. Available: http://pier.acponline.org/physicians/procedures/physpro1004/physpro1004.html 2012; Accessed Febraury 24, 2012.
8. Singh HS, Ekery DL. Cushings syndrome & the heart. AHA clinical cardiac consult book. In: Nixon JV, eds. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2010: 150-153.
9. Singh HS, Kirtane AJ, Moses JW. Angiosculpt scoring balloon catheter – an atherotomy device for coronary and peripheral interventions. Interventional Cardiology. 2010; 2(4): 469-478.
10. Dangas GD, Singh HS. Primary percutaneous coronary intervention in octogenarians: navigate with caution. Heart. 2010; 96(11): 813-814.
11. Singh HS, Bhave P. Acid base & electrolytes. In: Shah SJ, eds. UCSF Hospitalist Handbook. 3rd ed. San Francisco: University of California; 2008: 100-116.
12. Singh HS, Shah SK. Lower extremity edema & dyspnea in kampala, Uganda. HIV insight. In: Paul A, eds. Volberding. 2007. http://hivinsite.ucsf.edu/InSite?page=md-ccl-ca-06
13. Singh HS & Ekery DL. Cushings syndrome & the heart. In: Nixon JV, eds. AHA Clinical Cardiac Consult Book. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2006: 150-153.